I've been watching Washington for three decades. Seen presidents come and go, scandals break, insider trading investigations... but I've never seen the establishment this rattled.

A former White House insider just leaked something that has powerful people scrambling. We're talking about a handwritten document that could reshape how Americans think about the next four years. The kind of thing that doesn't stay buried for long.

The timing isn't coincidental. Someone with serious access decided now was the moment to go public. And when you see what's in this letter, you'll understand why certain D.C. power brokers are losing sleep.

This isn't politics — this is about positioning your money before everyone else catches on.


🔥 TODAY'S TOP 5 MOVERS

🥇 CYCN (Cyclerion Therapeutics,) $7.85 +403.9%
📰 Tisento Launches with $81 Million From Top-Tier Investor Syndicate and  |  📈 Vol: 149.9M
🥈 RENX (RenX Enterprises) $2.94 +64.6%
📰 RenX Enterprises Expands Contracted Inbound Volumes, Advancing Biomass  |  📈 Vol: 52.4M
🥉 HPAI (Helport AI Limited) $2.17 +44.8%
📰 Helport AI Reports Fiscal Full Year 2024 Financial Results  |  📈 Vol: 1.5M
4️⃣ AGPU (Axe Compute) $2.12 +32.7%
📰 Axe Compute Appoints Christopher Miglino as Chief Executive Officer, U  |  📈 Vol: 921K
5️⃣ TH (Target Hospitality) $12.15 +31.0%
📰 Target Hospitality (TH) Q2 Revenue Up 9%  |  📈 Vol: 3.9M

💡 BONUS BREAKDOWN: CYCN (Cyclerion Therapeutics,)

Cyclerion Therapeutics (CYCN) went absolutely parabolic yesterday, rocketing 403% from $1.55 to $7.85 on massive volume. Here's what actually happened.

The biotech company announced it closed an asset purchase agreement with Tisento, a newly launched company backed by $81 million from "top-tier investors." Cyclerion sold off key assets but retained equity ownership in Tisento plus got cash upfront. Classic biotech pivot play.

The secondary headline about Nasdaq compliance is just gravy — CYCN had been flirting with delisting due to low share price. Yesterday's surge fixed that problem in spectacular fashion.

Here's my read: This screams institutional money making a big bet on assets that Cyclerion couldn't properly monetize. The $81 million backing tells you smart money sees value here. But retail investors? You're late to the party.

The 400% gap-up means you missed the meat. Sure, biotech can run for days on momentum, but at these levels you're gambling, not investing. The risk-reward is upside down.

If you're determined to play momentum, wait for a pullback to the $4-5 range. Better yet, start tracking Tisento — that's where the real action might be once they go public.

Bottom line: Great trade if you owned it Monday. Dangerous chase if you're buying today. Biotech asset deals can create real value, but timing is everything.

Until tomorrow,
— Randy Cole, Editor, The Money Memo

The handwritten evidence changes everything — and it's all verified.

See what I found →

Keep Reading